Gilead Sciences Nears Acquisition of Ouro Medicines for Autoimmune Drug Development

Gilead Sciences is reportedly in advanced negotiations to acquire Ouro Medicines, a private company focused on developing innovative antibody treatments for autoimmune diseases. Bloomberg posted on X, highlighting the potential acquisition as part of Gilead's strategy to expand its portfolio in the autoimmune sector. Ouro Medicines has been working on novel therapies that could complement Gilead's existing offerings and enhance its position in the competitive pharmaceutical market. The acquisition discussions underscore Gilead's commitment to investing in cutting-edge research and development to address unmet medical needs in autoimmune conditions. Further details about the potential deal have not been disclosed, and both companies have yet to comment publicly on the matter.